Patent Expiries & Lackluster Pipeline Restrain Growth in the Ion Channel Modulators Market, According to a New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Ion Channel Modulators. The global market for Ion Channel Modulators is projected to decline to US$10.6 billion by 2018, on account of poor understanding about their complicated mode of action, impending patent expiries of leading drugs, and lack of adequate products in the pipeline.

Ion Channel Modulators: A Global Strategic Business Report

Follow us on LinkedIn – Despite data provided by the Human Genome Project regarding the use of ion channels as drug targets and the discovery of channelopathies, the use of ion channel modulators is limited by their extreme physiological, functional, and structural diversity, and restricted target validation for drug action. Insufficient research, patent expiries of branded drugs and generic competition, and lackluster pipeline are eroding revenue for ion channel modulators. Lyrica (by Pfizer) and Namenda XR (by Forest Laboratories) represent the leading ion channel modulators on the market. Though they are protected from generic competition by extended patents, the overall market situation remains grim. Due to ion channels’ highly complicated mode of action and inadequate research in the space, the market is restricted by very few products in the pipeline.

Ion channel modulators on the market currently include calcium channel blockers, such as amlodipine, and potassium channel blockers such as carbutamide, targeted against hypertension and diabetes, respectively. Neuropathic pain management represents a key therapeutic area because of the significance of ion channel transport in the nervous system and pain pathways. One of the few pipeline drugs, in fact, include TV-45070 by Teva Pharmaceuticals that acts against the novel target Nav1.7 ion channel within the pain transmission pathway. Initial trials of the drug showed positive results. Other therapeutic areas with potential include oncology, central nervous system disorders, epilepsy, among others.

As stated by the new market research report on Ion Channel Modulators, the United States represents the largest market, followed by Europe. The country accounts for an estimated 47.8% of the global market and is projected to shrink at a compounded annual rate of -3.2% over the analysis period. Likewise, Europe and all other regions globally are projected to record a negative CAGR.

The global Ion channel modulator market is led by Pfizer and Forest Labs, the developers of the top two revenue-grossing products, Lyrica and Namenda, respectively. The ion channel market is comprised of major pharmaceutical giants, as well as medium and small sized biotech companies, such as Convergence Pharmaceuticals Limited and Hydra Biosciences, that mainly focus on ion channel research and drug development. These small-sized companies enjoy competitive advantages, owing to their intense focus in the concerned area, highly skilled teams, as well as focus on libraries of specific compounds for screening. Consequently, around 65% of the ion channel drugs under development belong to medium to small-sized companies.

Major players in the market include AstraZeneca, Bayer HealthCare, CalciMedica Inc., Convergence Pharmaceuticals Ltd., Evotec AG, Forest Laboratories LLC, GlaxoSmithKline Plc., Johnson & Johnson, Lundbeck, Novartis AG, Parion Sciences Inc., Pfizer Inc., Sanofi, Targacept Inc., and Xention Limited, among others.

The research report titled “Ion Channel Modulators: A Global Strategic Business Report” announced by the Global Industry Analysts Inc., provides a comprehensive review of market trends, issues and concerns, future prospects, recent industry activity, and profiles of major and niche global as well as regional market participants. The report provides market estimates and projections in US$ for all major geographic markets, including the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, and Rest of Asia-Pacific), Latin America (Brazil and Rest of Latin America), and Rest of World.

For more details about this comprehensive market research report, please click here

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes 1500+ full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site:

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website